MX2020002553A - Metodos de diagnostico y terapeuticos para el cancer. - Google Patents

Metodos de diagnostico y terapeuticos para el cancer.

Info

Publication number
MX2020002553A
MX2020002553A MX2020002553A MX2020002553A MX2020002553A MX 2020002553 A MX2020002553 A MX 2020002553A MX 2020002553 A MX2020002553 A MX 2020002553A MX 2020002553 A MX2020002553 A MX 2020002553A MX 2020002553 A MX2020002553 A MX 2020002553A
Authority
MX
Mexico
Prior art keywords
cancer
methods
individual
diagnostic
therapeutic methods
Prior art date
Application number
MX2020002553A
Other languages
English (en)
Inventor
Christiaan Nicolaas Klijn
Shiva Malek
Ivana Yen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2020002553A publication Critical patent/MX2020002553A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención proporciona métodos de diagnóstico y terapéuticos y composiciones para el cáncer. La invención proporciona métodos para determinar si un individuo que tiene un cáncer tiene probabilidades de responder al tratamiento que comprende un pan-inhibidor de dímero de RAF y un inhibidor de MEK o PI3K, métodos para predecir la sensibilidad de un individuo que tiene un cáncer al tratamiento que comprende un pan-inhibidor de dímero de RAF y un inhibidor de MEK o PI3K, métodos para seleccionar una terapia para un individuo que tiene un cáncer y métodos para tara a un individuo que tiene cáncer basándose en la presencia de un biomarcador de la invención (por ejemplo, una mutación activante de KRAS, por ejemplo, una mutación KRAS-G13D o una mutación activante de NRAS).
MX2020002553A 2017-09-08 2018-09-07 Metodos de diagnostico y terapeuticos para el cancer. MX2020002553A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762556277P 2017-09-08 2017-09-08
PCT/US2018/050056 WO2019051296A1 (en) 2017-09-08 2018-09-07 DIAGNOSTIC AND THERAPEUTIC METHODS OF CANCER

Publications (1)

Publication Number Publication Date
MX2020002553A true MX2020002553A (es) 2020-07-22

Family

ID=63714054

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002553A MX2020002553A (es) 2017-09-08 2018-09-07 Metodos de diagnostico y terapeuticos para el cancer.

Country Status (11)

Country Link
US (1) US11859252B2 (es)
EP (1) EP3679159A1 (es)
JP (2) JP2020532982A (es)
KR (1) KR20200041387A (es)
CN (1) CN111373055A (es)
AU (1) AU2018329925A1 (es)
CA (1) CA3073073A1 (es)
IL (1) IL273071A (es)
MX (1) MX2020002553A (es)
TW (1) TWI827550B (es)
WO (1) WO2019051296A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI782906B (zh) 2016-03-04 2022-11-11 日商大鵬藥品工業股份有限公司 惡性腫瘤治療用製劑及組合物
CA3073073A1 (en) 2017-09-08 2019-03-14 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for cancer
EP4134081A4 (en) * 2020-04-10 2024-05-01 Taiho Pharmaceutical Co Ltd CANCER THERAPY USING 3,5-DISUBSTITUTED ALCYNYL BENZENE COMPOUND AND MEK INHIBITOR
CN115916346A (zh) * 2020-04-27 2023-04-04 维瑞斯特姆股份有限公司 用于治疗异常细胞生长的方法
EP4203963A1 (en) * 2020-08-31 2023-07-05 Novartis AG Combination therapy of a raf inhibitor and a mek inhibitor for the treatment of sarcoma
CN112889760A (zh) * 2021-02-28 2021-06-04 三江县连兴蛇业有限公司 一种虫茶生产大棚及虫茶生产方法
CN117561062A (zh) * 2021-04-06 2024-02-13 基因泰克公司 使用贝伐拉非尼和考比替尼或使用贝伐拉非尼、考比替尼和阿特珠单抗的组合疗法
CN113862364A (zh) * 2021-10-25 2021-12-31 天津市肿瘤医院（天津医科大学肿瘤医院） 结直肠癌诊断标志物、pap检测探针以及结直肠癌的检测试剂盒
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
CN116570599B (zh) * 2023-07-04 2023-10-20 四川大学华西医院 Vs6766联合ly3009120的应用及药物组合物

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4998617A (en) 1986-09-15 1991-03-12 Laura Lupton Inc Facial cosmetic liquid make up kit
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
CA2066428C (en) 1989-09-08 2000-11-28 Bert Vogelstein Structural alterations of the egf receptor gene in human gliomas
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
ATE207366T1 (de) 1993-12-24 2001-11-15 Merck Patent Gmbh Immunokonjugate
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508537D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
BR9609617B1 (pt) 1995-07-06 2010-07-27 derivados de 7h-pirrol[2,3-d]pirimidina, e composição farmacêutica.
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
CA2249446C (en) 1996-04-12 2008-06-17 Warner-Lambert Company Irreversible inhibitors of tyrosine kinases
AU3766897A (en) 1996-07-13 1998-02-09 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
JP4327259B2 (ja) 1997-05-06 2009-09-09 ワイス・ホールディングズ・コーポレイション 多発性嚢胞腎の治療のためのキナゾリン化合物の使用
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
CA2303206A1 (en) 1997-09-10 1999-03-18 University Of Maryland, Baltimore Method of amplifying dna and rna mismatch cleavage products
NZ503991A (en) 1997-11-06 2001-11-30 American Cyanamid Co Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
NZ512189A (en) 1998-11-19 2003-10-31 Warner Lambert Co N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4- yl-propoxy)-quinazolin-6-yl]-acrylamide useful as an irreversible inhibitor of tyrosine kinases
DK1696920T3 (en) 2003-12-19 2015-01-19 Plexxikon Inc RELATIONS AND PROCEDURES FOR THE DEVELOPMENT OF LAW MODULATORS
DK1893612T3 (da) 2005-06-22 2011-11-21 Plexxikon Inc Pyrrol [2,3-B]pyridin-derivater som proteinkinasehæmmere
ATE504565T1 (de) 2005-10-07 2011-04-15 Exelixis Inc Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
US7893085B2 (en) 2006-08-21 2011-02-22 Genentech, Inc Aza-benzothiophenyl compounds and methods of use
MX2009001878A (es) 2006-08-21 2009-03-03 Genentech Inc Compuestos de aza-benzofuranilo y metodos de uso.
CL2007003444A1 (es) 2006-11-30 2008-06-27 Genentech Inc Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria.
PE20121126A1 (es) 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
JP5580735B2 (ja) 2007-06-12 2014-08-27 ジェネンテック， インコーポレイテッド Ｎ−置換アザインドール類及び使用方法
PE20091158A1 (es) 2007-12-19 2009-08-28 Genentech Inc 5-anilinoimidazopiridinas y metodos de uso
KR20100101666A (ko) 2007-12-19 2010-09-17 제넨테크, 인크. ８-아닐리노이미다조피리딘 및 항암제 및/또는 소염제로서의 이들의 용도
KR20100099185A (ko) 2007-12-21 2010-09-10 제넨테크, 인크. 아자인돌리진 및 이용 방법
MX2010014559A (es) 2008-07-01 2011-03-04 Genentech Inc Heterociclos bicíclicos sustituidos y metodos de uso.
MX2010014565A (es) 2008-07-01 2011-03-04 Genentech Inc Isoindolona y metodos de uso.
US20100286143A1 (en) 2009-04-24 2010-11-11 Dora Dias-Santagata Methods and materials for genetic analysis of tumors
US20130004481A1 (en) 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
EP2681215B1 (en) 2011-02-28 2015-04-22 Array Biopharma, Inc. Serine/threonine kinase inhibitors
ES2552989T3 (es) 2011-08-04 2015-12-03 Array Biopharma, Inc. Compuestos de quinazolina como inhibidores de la cinasa de serina / treonina
BR122019019582B1 (pt) 2011-12-30 2021-07-13 Hanmi Pharm. Co., Ltd. Compostos derivados de tieno[3,2-d]pirimidina, composição farmacêutica contendo os ditos compostos e uso dos mesmos para a prevenção ou tratamento de uma doença causada por ativação anormal de uma proteína quinase
AR090220A1 (es) 2012-03-01 2014-10-29 Array Biopharma Inc Inhibidores de serina/treonina cinasa
BR112014029338A2 (pt) 2012-05-31 2017-06-27 Bayer Pharma AG biomarcadores para determinação da resposta eficaz dos tratamentos de pacientes com carcinoma hepatocelular (hcc)
JP6378182B2 (ja) 2012-08-27 2018-08-22 アレイ バイオファーマ、インコーポレイテッド 過剰増殖性│疾患の処置のためのセリン／スレオニンキナーゼ阻害剤
CN104755478B (zh) 2012-10-16 2017-10-10 霍夫曼-拉罗奇有限公司 丝氨酸/苏氨酸激酶抑制剂
WO2014089241A2 (en) * 2012-12-04 2014-06-12 Caris Mpi, Inc. Molecular profiling for cancer
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
CR20160309A (es) 2013-12-06 2016-08-25 Genentech Inc Inhibidores de serina/treonina cinasa
BR112016015235A2 (pt) 2013-12-30 2017-08-08 Genentech Inc Composto, composição farmacêutica, método de inibição da atividade da proteína quinase erk e método de tratamento
MX2016008624A (es) 2013-12-30 2017-01-06 Genentech Inc Inhibidores de serina/treonina cinasa.
MY188526A (en) 2014-04-09 2021-12-18 Genentech Inc Process for the manufacturing of medicaments
EP2955522A1 (en) 2014-06-13 2015-12-16 Fundació Privada Institut d'Investigació Oncològica de Vall Hebron A method for monitoring the treatment of patients with tumors expressing EGFR
EP3161151A1 (en) 2014-06-24 2017-05-03 Abbott Molecular Inc. Detection of single nucleotide polymorphisms in human kras
LT3319993T (lt) 2015-07-10 2020-05-11 Genmab A/S Axl specifiniai antikūno-vaistokonjugatai, skirti vėžiui gydyti
CA3073073A1 (en) 2017-09-08 2019-03-14 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for cancer

Also Published As

Publication number Publication date
IL273071A (en) 2020-04-30
AU2018329925A1 (en) 2020-03-05
KR20200041387A (ko) 2020-04-21
TWI827550B (zh) 2024-01-01
WO2019051296A1 (en) 2019-03-14
EP3679159A1 (en) 2020-07-15
JP2020532982A (ja) 2020-11-19
TW201919707A (zh) 2019-06-01
JP2023182572A (ja) 2023-12-26
US11859252B2 (en) 2024-01-02
US20200190596A1 (en) 2020-06-18
CA3073073A1 (en) 2019-03-14
CN111373055A (zh) 2020-07-03
AU2018329925A8 (en) 2020-03-19

Similar Documents

Publication Publication Date Title
MX2020002553A (es) Metodos de diagnostico y terapeuticos para el cancer.
MX2023006766A (es) Composiciones que comprenden inhibidores de shp2 y metodos para tratar el cancer.
MX2022006075A (es) Antagonistas de union a pd-l1 y usos de los mismos para el tratamiento de cancer.
MX2020000604A (es) Métodos terapéuticos y de diagnóstico para el cáncer.
EP4085919A3 (en) Compositions and methods to treat cancer
MX2023002251A (es) Antagonistas de union al eje pd-l1 y usos de los mismos para el tratamiento de cancer.
PH12018502355A1 (en) Enzyme inhibitors
EA201791258A1 (ru) Комбинированная терапия с применением ингибитора ацетил-коа-карбоксилазы (acc) для лечения неалкогольной жировой болезни печени
MX2018012471A (es) Metodos de diagnostico y terapeuticos para el cancer.
CY1124951T1 (el) Συνδυαστικη θεραπεια για την αντιμετωπιση των κακοηθειων
MX2017005929A (es) Terapia de combinacion con agonistas de unión ox40 e inhibidores de tigit.
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
MX2021012977A (es) Tratamiento del cáncer con tg02.
WO2017214373A8 (en) Diagnostic and therapeutic methods for cancer
BR112017028530A2 (pt) terapia combinada para tratamento de cânceres hematológicos e tumores sólidos
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
BR112017021312A2 (pt) tratamento de câncer de pulmão com inibidores de glutaminase
MY183503A (en) Method of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
MX2023005747A (es) Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos.
MX2018006781A (es) Inhibidores de mat2a para el tratamiento del cancer que no expresen mtap.
MX2020011684A (es) Inhibicion combinada de pd-1/pd-l1, tgfbeta y dna-pk para el tratamiento del cancer.
EA201791736A1 (ru) Комбинированная терапия для лечения рака
EA201990567A1 (ru) Комбинированная терапия с ингибиторами глутаминазы
MX2017014547A (es) Secuencias de uricasa mejoradas y metodos de tratamiento.